Patent Term Extensions for Regulatory Delays

Introduction

Patent term extension (PTE) is a legal mechanism that allows eligible patent holders to recover part of the patent protection lost while obtaining mandatory regulatory approval for products such as pharmaceutical medicines, biologics and medical devices. These products often require extensive safety testing, clinical trials and regulatory evaluation before they can be marketed.

Because this process can consume a substantial portion of a patent's 20-year term, some jurisdictions provide limited extensions to encourage investment in research and development. However, an extension must satisfy statutory conditions and is not automatically granted whenever regulatory approval takes time.

In India, the Patents Act, 1970, generally provides a 20-year patent term under Section 53, calculated from the relevant filing date. India does not currently provide a general patent-term extension mechanism specifically compensating for pharmaceutical regulatory delays. The United States and the European Union have separate statutory frameworks for certain eligible products.

IndiaCode

+1

1. Legal Framework and Objectives

Patent term extension systems generally seek to:

Compensate eligible innovators for qualifying periods spent obtaining regulatory approval.

Encourage investment in pharmaceutical research, clinical trials and product development.

Preserve incentives to develop complex medicines and biologics.

Balance innovation incentives against the need for timely generic and biosimilar competition.

In the United States, 35 U.S.C. § 156 provides a mechanism for extending certain patent terms following regulatory review. In the European Union, supplementary protection certificates (SPCs), governed by applicable EU legislation, can provide additional protection for qualifying medicinal and plant-protection products.

These mechanisms are distinct from patent-term adjustment for delays caused by patent offices during examination.

2. Eligibility and Calculation of Extension

Under US law, 35 U.S.C. § 156 generally permits an extension of up to five years for an eligible patent covering a qualifying product, use or manufacturing method. The extension is subject to statutory requirements, including qualifying regulatory review, first permitted commercial marketing in the relevant category, and timely application. The extended patent term generally cannot exceed 14 years after regulatory approval.

U.S. Code

+1

3. Important Case Laws

A. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990)

The US Supreme Court examined the relationship between patent-term extension under Section 156 and the regulatory-review exemption under Section 271(e)(1). The Court explained that the Hatch–Waxman Act sought to address the loss of effective patent protection during regulatory approval while also allowing competitors to undertake qualifying regulatory preparation before patent expiry.

Legal principle: Patent-term extension and regulatory-review exceptions must be interpreted as parts of a coordinated statutory framework.

LII / Legal Information Institute

+1

B. Merck & Co. v. Hi-Tech Pharmacal Co., 482 F.3d 1317 (Fed. Cir. 2007)

The dispute concerned Merck's patent covering the glaucoma medicine TRUSOPT and a previously filed terminal disclaimer. The court held that the disclaimer did not automatically prevent an extension under Section 156 where the statutory requirements were satisfied.

Legal principle: Eligibility for restoration depends on the specific statutory language; a terminal disclaimer does not necessarily defeat a qualifying regulatory-delay extension.

Justia Law

+1

C. Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010)

The Federal Circuit addressed how patent-term adjustment should be calculated for delays attributable to the US Patent and Trademark Office. Although the case concerned administrative prosecution delays rather than regulatory approval, it clarifies that patent-term adjustment and regulatory patent-term extension are separate mechanisms governed by different statutory provisions.

4. Indian Position

Section 53 of India's Patents Act, 1970, generally fixes the patent term at 20 years from the relevant filing date. Unlike the US framework, Indian law does not provide a general extension solely to compensate for pharmaceutical regulatory delays.

IndiaCode

+1

Conclusion

Patent-term extensions address the time lost during mandatory regulatory review, but they remain subject to statutory eligibility, calculation limits and procedural deadlines. The US cases demonstrate the importance of interpreting extension provisions precisely, while India's Section 53 reflects a different legislative approach. A balanced framework must encourage pharmaceutical innovation without unnecessarily delaying generic competition or access to affordable medicines.